# NiKang Therapeutics

**Canonical:** https://apis.io/providers/nikang-therapeutics/  
**Website:** https://www.nikangtx.com/  
**APIs profiled:** 9

NiKang Therapeutics is a clinical-stage biotechnology company headquartered at 200 Powder Mill Road, Building E500, Wilmington, Delaware, founded in 2017 to discover and develop innovative small molecule medicines that help patients fight cancer. The company works from deep insights into disease biology and molecular pathways and applies structure-based drug design to targets long considered difficult to drug, spanning both inhibitor and targeted-protein-degradation modalities. Its lead programme, NKT2152, is an orally bioavailable allosteric HIF2alpha inhibitor in Phase 1/2 for clear cell renal cell carcinoma, VHL disease and other solid tumours; NKT3964 is a first-in-class selective CDK2 degrader in Phase 1 for advanced or metastatic solid tumours; NKT5097 is a first-in-class dual CDK2/4 degrader, also in Phase 1; and a KRAS G12D small molecule programme sits in discovery and IND-enabling work. NiKang raised a $10 million Series A in December 2017, a $50 million Series B in September 2020 and a $200 million Series C in May 2021, and has partnered its chemistry with Erasca on SHP2 and with Pfizer, Hansoh and Roche on HIF2. NiKang Therapeutics runs no developer program and publishes no product API, developer portal, API reference or machine-readable specification of its own. The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.nikangtx.com, which is catalogued here — 210 registered routes across 17 namespaces, of which the anonymously readable read-only content families are described in openapi/.

## Kin Score — 31.7 / 100 (thin)

Scored 2026-09-02 under rubric 0.18.0. Trend: flat (+0.0 from 31.7).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 48.5 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 13.7 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 48.8 (matched via tags).

## Agent readiness — 25.5 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | documented |
| Auth Clarity | bearer |
| Idempotency | no |
| Error Semantics | verified |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Access

Open access — onboarding: open, pricing: unknown, trial: no (confidence: medium).

## APIs (9)

- **NiKang Therapeutics Posts API** — News archive — press releases, clinical data announcements and scientific presentations. Sixteen posts published at harvest time, all in the `news` category.
- **NiKang Therapeutics Pages API** — Corporate pages — about us, science and pipeline, news, careers, jobs, privacy policy and terms of use. Nine pages published at harvest time.
- **NiKang Therapeutics Team API** — The7 theme `dt_team` custom post type carrying NiKang's named people — ten published at harvest time, split by the dt_team_category taxonomy into Board (7) and Officers (2). The...
- **NiKang Therapeutics Media API** — Media library — logos, leadership headshots, pipeline graphics and press assets. Sixty-seven attachments present at harvest time.
- **NiKang Therapeutics Taxonomy API** — Categories, tags and team categories, plus the taxonomy registry. Three post categories are registered (`news` with 16 posts, `timeline` and `uncategorized` both empty); the pos...
- **NiKang Therapeutics Search API** — Cross-content search across every published object — posts, pages, dt_team members and terms — in one call. Returned six matches for `cdk2` at harvest time.
- **NiKang Therapeutics Discovery API** — Route, post-type, taxonomy and status discovery documents. The /wp-json index publishes the full 210-route table across 17 namespaces and is the machine-readable contract this w...
- **NiKang Therapeutics Comments API** — Comment collection. Registered and anonymously reachable, but empty — no object on this deployment carries comments.
- **NiKang Therapeutics oEmbed API** — oEmbed 1.0 provider endpoint for www.nikangtx.com URLs. Verified live and anonymous — returns provider_name "Nikang Therapeutics" for the site root.

## MCP servers (1)

- **NiKang Therapeutics MCP Server**

## Security (2)

- **Nikang Therapeutics Authentication** — 0 schemes
- **Nikang Therapeutics Domain Security** — TLSv1.3 · DMARC

## Plans (1)

- **Nikang Therapeutics Plans Pricing**

## Tags

Company, Biotechnology, Pharmaceuticals, Oncology, Precision Medicine, Drug Discovery, Targeted Protein Degradation, Clinical Trials, Life Sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/nikang-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.